Androgen Receptor Antagonists
-
Subject Areas on Research
-
Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.
-
Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line.
-
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
-
Androgen receptor variant-driven prostate cancer II: advances in clinical investigation.
-
Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.
-
Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
-
Beyond aggression: Androgen-receptor blockade modulates social interaction in wild meerkats.
-
Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors.
-
Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display.
-
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
-
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
-
Enzalutamide in metastatic prostate cancer before chemotherapy.
-
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.
-
Increased survival with enzalutamide in prostate cancer after chemotherapy.
-
Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
-
Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.
-
Inhibition of androgen receptor-dependent transcriptional activity by DDT isomers and methoxychlor in HepG2 human hepatoma cells.
-
Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists.
-
Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.
-
Molecular determinants for enzalutamide-induced transcription in prostate cancer.
-
New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches.
-
Novel therapies are changing treatment paradigms in metastatic prostate cancer.
-
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
-
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
-
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.
-
Research priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia.
-
Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer.
-
Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells.
-
Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.
-
Targeting the androgen receptor--theory and practice.
-
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
-
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.
-
Keywords of People